Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report)'s stock price traded up 1.9% during mid-day trading on Friday . The stock traded as high as $5.89 and last traded at $5.32. 647,470 shares traded hands during trading, a decline of 48% from the average session volume of 1,254,936 shares. The stock had previously closed at $5.22.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the company. Maxim Group lowered Citius Oncology from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Citigroup lowered Citius Oncology to a "hold" rating in a research report on Friday, May 23rd.
Get Our Latest Analysis on Citius Oncology
Citius Oncology Price Performance
The company has a current ratio of 0.36, a quick ratio of 0.05 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average of $1.67 and a 200-day moving average of $1.23.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Citius Oncology stock. Citadel Advisors LLC acquired a new stake in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 22,699 shares of the company's stock, valued at approximately $26,000. 70.52% of the stock is currently owned by institutional investors.
Citius Oncology Company Profile
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Featured Articles
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
